AGARWALEYE Dr. Agarwal's Health Care Q4 FY25 results (Jan–Mar 2025) and concall
Dr. Agarwal's Health Care Limited reported strong financial performance for FY25 and Q4 FY25, driven by robust revenue growth and strategic facility expansion. While EBITDA margins were impacted by higher operating costs and one-time expenses, the company is optimistic about future growth, targeting 20%+ revenue and 35%+ PAT growth for FY26, supported by significant capex plans for new facilities and technology upgrades.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 255 | 268 | 281 |
| EBITDA | 58 | 65 | 73 |
| Net profit | -4 | 8 | 27 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
